Detalhe da pesquisa
1.
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Clin Infect Dis
; 78(4): 870-879, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37967326
2.
Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.
J Infect Dis
; 220(7): 1127-1135, 2019 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31505665
3.
Accelerating Vaccine Development During the 2013-2016 West African Ebola Virus Disease Outbreak.
Curr Top Microbiol Immunol
; 411: 229-261, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28918539
4.
Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
J Infect Dis
; 215(12): 1789-1798, 2017 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28549145
5.
Identification of immune correlates of protection in Shigella infection by application of machine learning.
J Biomed Inform
; 74: 1-9, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28802838
6.
Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
Clin Infect Dis
; 62(11): 1329-1335, 2016 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27001804
7.
Immunology of gut mucosal vaccines.
Immunol Rev
; 239(1): 125-48, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21198669
8.
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial.
Lancet Infect Dis
; 24(3): 308-318, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38061367
9.
Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a.
Clin Immunol
; 148(1): 35-43, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23649043
10.
Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates.
Cell Rep
; 42(4): 112402, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37061918
11.
Association Between State Hepatitis A Vaccination Requirements and Hepatitis A Vaccination Rates.
J Pediatric Infect Dis Soc
; 11(6): 295-299, 2022 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385115
12.
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
Vaccine
; 40(9): 1342-1351, 2022 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35039194
13.
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
Vaccine
; 40(46): 6599-6606, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36208978
14.
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
AIDS
; 36(3): 373-382, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34750291
15.
Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
Clin Immunol
; 138(2): 187-200, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21146460
16.
Effects of Gamma Irradiation of Human Serum Samples from rVSVΔG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays.
Am J Trop Med Hyg
; 104(5): 1751-1754, 2021 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33782211
17.
Development of Pandemic Vaccines: ERVEBO Case Study.
Vaccines (Basel)
; 9(3)2021 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33668698
18.
Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA™).
Vaccine
; 39(20): 2764-2771, 2021 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33867215
19.
Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.
Lancet Microbe
; 2(2): e70-e78, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35544244
20.
Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus - Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis.
Vaccine
; 38(31): 4885-4891, 2020 06 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499064